How to buy ZIOPHARM Oncology stock

ZIOPHARM Oncology, Inc is a biotechnology business based in the US. ZIOPHARM Oncology shares (ZIOP) are listed on the NASDAQ and all prices are listed in US Dollars. ZIOPHARM Oncology employs 103 staff and has a market cap (total outstanding shares value) of 0.00.

ZIOPHARM Oncology share price

Use our graph to track the performance of ZIOP stocks over time.

ZIOPHARM Oncology shares at a glance

• Key figures

Information last updated 2021-04-23.

52-week range	$2.06 - $5.95
50-day moving average	$3.76
200-day moving average	$3.39
Wall St. target price	$5.67
PE ratio	4.3467
Dividend yield	N/A (0%)
Earnings per share (TTM)	$0.58

Buy ZIOPHARM Oncology shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy ZIOPHARM Oncology stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of ZIOPHARM Oncology, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is ZIOPHARM Oncology under- or over-valued?

Valuing ZIOPHARM Oncology stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of ZIOPHARM Oncology's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

ZIOPHARM Oncology's P/E ratio

ZIOPHARM Oncology's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 4x. In other words, ZIOPHARM Oncology shares trade at around 4x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

ZIOPHARM Oncology financials

Gross profit TTM	$-52,696,000
Return on assets TTM	-39.32%
Return on equity TTM	-73.04%
Profit margin	0%
Book value	$0.58
Market capitalisation	$719.9 million

TTM: trailing 12 months

Shorting ZIOPHARM Oncology shares

There are currently 39.4 million ZIOPHARM Oncology shares held short by investors – that's known as ZIOPHARM Oncology's "short interest". This figure is 11.3% up from 35.4 million last month.

There are a few different ways that this level of interest in shorting ZIOPHARM Oncology shares can be evaluated.

ZIOPHARM Oncology's "short interest ratio" (SIR)

ZIOPHARM Oncology's "short interest ratio" (SIR) is the quantity of ZIOPHARM Oncology shares currently shorted divided by the average quantity of ZIOPHARM Oncology shares traded daily (recently around 2.6 million). ZIOPHARM Oncology's SIR currently stands at 15.07. In other words for every 100,000 ZIOPHARM Oncology shares traded daily on the market, roughly 15070 shares are currently held short.

However ZIOPHARM Oncology's short interest can also be evaluated against the total number of ZIOPHARM Oncology shares, or, against the total number of tradable ZIOPHARM Oncology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ZIOPHARM Oncology's short interest could be expressed as 0.18% of the outstanding shares (for every 100,000 ZIOPHARM Oncology shares in existence, roughly 180 shares are currently held short) or 0.1933% of the tradable shares (for every 100,000 tradable ZIOPHARM Oncology shares, roughly 193 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against ZIOPHARM Oncology.

Find out more about how you can short ZIOPHARM Oncology stock.

ZIOPHARM Oncology share dividends

We're not expecting ZIOPHARM Oncology to pay a dividend over the next 12 months.

Have ZIOPHARM Oncology's shares ever split?

ZIOPHARM Oncology's shares were split on a 1:40 basis on 23 August 2005. So if you had owned 40 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your ZIOPHARM Oncology shares – just the quantity. However, indirectly, the new 3900% higher share price could have impacted the market appetite for ZIOPHARM Oncology shares which in turn could have impacted ZIOPHARM Oncology's share price.

ZIOPHARM Oncology share price volatility

Over the last 12 months, ZIOPHARM Oncology's shares have ranged in value from as little as $2.06 up to $5.95. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ZIOPHARM Oncology's is 2.0871. This would suggest that ZIOPHARM Oncology's shares are significantly more volatile than the average for this exchange and represent a higher risk.

ZIOPHARM Oncology overview

ZIOPHARM Oncology, Inc. , a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies to treat patients with cancer. The company develops Sleeping Beauty platform, which is based on the non-viral genetic engineering of immune cells using a transposon/transposase system to engineer T-cells outside of the body for infusion; and Controlled IL-12 to stimulate expression of interleukin 12 or IL-12, a master regular of the immune system, in a controlled manner to focus the patient's immune system to attack cancer cells. Its product candidates include T cell receptor + T therapies to target solid tumors; chimeric antigen receptor + T cell therapies targeting CD19 for hematologic malignancies; and Ad-RTS-hIL-12 plus veledimex, a gene delivery system to regulate production of IL-12 to treat patients with recurrent glioblastoma multiforme in adults. The company has a license agreement with PGEN Therapeutics, Inc. ; research and development agreement with The University of Texas MD Anderson Cancer Center; a patent license agreement with the National Cancer Institute; and a cooperative research and development agreement with the National Cancer Institute. ZIOPHARM Oncology, Inc.

Frequently asked questions

• What percentage of ZIOPHARM Oncology is owned by insiders or institutions?

  Currently 9.598% of ZIOPHARM Oncology shares are held by insiders and 57.108% by institutions.

• How many people work for ZIOPHARM Oncology?

  Latest data suggests 103 work at ZIOPHARM Oncology.

• When does the fiscal year end for ZIOPHARM Oncology?

  ZIOPHARM Oncology's fiscal year ends in December.

• Where is ZIOPHARM Oncology based?

  ZIOPHARM Oncology's address is: Parris Building 34, Boston, MA, United States, 02129

• What is ZIOPHARM Oncology's ISIN number?

  ZIOPHARM Oncology's international securities identification number is: US98973P1012

• What is ZIOPHARM Oncology's CUSIP number?

  ZIOPHARM Oncology's Committee on Uniform Securities Identification Procedures number is: 98973P101